Tag: glaucoma
Nicox: Presentation at the World Glaucoma Congress of Data on NCX 470 from the Adaptive Dose Selection Step of the Phase 3 Mont Blanc Study and Analysis of Patient Subgroups Showing Superiority of NCX 470 compared to latanoprost – 07/03/2023 at 07:41
Nicox announced that additional data on NCX 470 was presented at the 10th World Glaucoma Congress (WGC) held from June 28 to July 1, 2023 in Rome, Italy. NCX 470…
For Kepler Cheuvreux, the experimental treatment of Nicox against glaucoma “must improve its efficacy profile”
Posted Jan 10, 2023, 3:32 PMUpdated Jan 10, 2023, 3:34 PM Nicox has been kept out of the rebound in biotechnology stocks since the start of the year. Today, the…
Glaucoma: the list of foods to avoid: Femme Actuelle Le MAG
Glaucoma: the list of foods to avoid: Femme Actuelle Le MAG Path 2 645DBCB3-7979-441A-BA4B-98E7BF17E1BE 1785B508-2A96-4CF5-AA87-79B0FE0441BF advertisement source site-45
Glaucoma (operation): what does the surgery consist of? : Current Woman Le MAG
Glaucoma (operation): what does the surgery consist of? : Current Woman Le MAG Path 2 645DBCB3-7979-441A-BA4B-98E7BF17E1BE 1785B508-2A96-4CF5-AA87-79B0FE0441BF advertisement source site-44
Nicox: Development and partnership plans for NCX 470 in glaucoma – 07/11/2022 at 07:37
Nicox SA, an international company specializing in ophthalmology, today announces development and partnership plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 clinical…
Nicox: positive phase 3 data in glaucoma – 10/31/2022 at 08:18
(CercleFinance.com) – The Nicox ophthalmology laboratory announces that the first of two phase 3 studies on its NCX 470 in glaucoma, the Mont Blanc study, has reached the efficacy required…
Nicox: NCX 470 has achieved the primary objective of the Mont Blanc study (glaucoma) – 31/10/2022 at 10:07
(AOF) – Nicox SA, an international specialty ophthalmology company, today announces that NCX 470 0.1% administered once daily has achieved the primary endpoint of non-inferiority in the reduction of intraocular…
Nicox: positive phase 3 data in glaucoma
(CercleFinance.com) – The ophthalmology laboratory Nicox announces that the first of two phase 3 studies on its NCX 470 in glaucoma, the Mont Blanc study, has reached the efficacy required…
Nicox: phase 2 study published by the Journal of Glaucoma – 04/11/2022 at 12:08
(Photo credits: Pixabay – fernando zhiminaicela) (AOF) – Nicox jumped 10% to 1.84 euros. This morning, the company announced the publication of the results of the Dolomites Phase 2 clinical…
Nicox: Results of the Dolomites Phase 2 clinical study of NCX 470 published in the Journal of Glaucoma – 04/11/2022 at 07:40
Nicox today announces the publication of the results of the Phase 2 Dolomites clinical study of NCX 470 in patients with open-angle glaucoma or ocular hypertension in the Journal of…
“Like stabs”: Elisabeth Quin evokes the double glaucoma which complicates her life
Suffering from double glaucoma, Elisabeth Quin had to find solutions to be able to continue to host her program 28 Minutes. In 2019, the journalist revealed that she had to…